Abstract:Background:: The research and development of HIV drugs is very important, but at the same time it is a long cycle and expensive system project. High-throughput drug screening systems and molecular libraries of potential hit compounds remain the main ways for the discovery of hit compounds with anti-HIV activity. Objective:: The aim of this study was to screen out the hit compounds against HIV-1 in the natural product molecule library and the antiviral molecule library, and elucidate the molecular mechanism of their inhibition of HIV-1, so as to provide a new choice for AIDS drug research. Methods:: In this study, a drug screening system using HIV Rev-dependent indicator cell line (Rev-A3R5-GFP reporter cells) with pseudoviruses (pNL4-3) was used. The natural drug molecule library and antiviral molecule library were screened, and preliminary drug mechanism studies were performed. Results:: Ten promising hit compounds were screened. These ten molecules and their drug inhibitory IC50 were as follows: Cephaeline (0.50 μM), Yadanziolide A (8.82 μM), Bruceine D (2.48 μM), Astragaloside IV (4.30 μM), RX-3117 (1.32 μM), Harringtonine (0.63 μM), Tubercidin (0.41 μM), Theaflavine-3, 3'-digallate (0.41 μM), Ginkgetin (10.76 μM), ZK756326 (5.97 μM). The results of the Time of additions showed that except for Astragaloside IV and Theaflavine-3, 3'-digallate had a weak entry inhibition effect, and it was speculated that all ten compounds had an intracellular inhibition effect. Cephaeline, Harringtonine, Astragaloside IV, Bruceine D, and Tubercidin may have pre-reverse transcriptional inhibition. Yadanziolide A, Theaflavine-3, 3'-digallate, Ginkgetin and RX-3117 may be in the post-reverse transcriptional inhibition. The inhibitory effect of ZK 75632 may be in the reverse transcriptional process. Conclusion:: A drug screening system using Rev-A3R5-GFP reporter cells with pseudoviruses (pNL4-3) is highly efficient. This study provided potential hit compounds for new HIV drug research.

Current Status of Targets and Assays for Anti-Hiv Drug Screening

Progress on AIDS drug targets and small molecule inhibitors

Novel Drug Targets for Anti-Hiv-1 Therapy

Opportunities and challenges in new HIV therapeutic discovery: what is the next step?

Hiv Drug Resistance And Its Impact On Antiretroviral Therapy In Chinese Hiv-Infected Patients

Current status of the small molecule anti-HIV drugs in the pipeline or recently approved

Anti-HIV Drug Development Through Computational Methods

Advances in Biosensing Strategies for HIV-1 Detection, Diagnosis, and Therapeutic Monitoring

Research Status Quo and Development Trend of Anti - HIV Drugs

Point-of-Care Tests for HIV Drug Resistance Monitoring: Advances and Potentials

Development of Anti-HIV Therapeutics: From Conventional Drug Discovery to Cutting-Edge Technology

Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.

A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication

Discovery of Ten Anti-HIV Hit Compounds and Preliminary Pharmacological Mechanisms Studies

High-throughput Screening Using Pseudotyped Lentiviral Particles: a Strategy for the Identification of HIV-1 Inhibitors in a Cell-Based Assay.

The advances of anti-HIV-1 drugs

Targeting Protein-Protein Interactions: a Promising Avenue of Anti-Hiv Drug Discovery.

Recent Advances in Computer-aided Antiviral Drug Design Targeting HIV-1 Integrase and Reverse Transcriptase Associated Ribonuclease H

Clinical Development and Application of HIV Entry Inhibitors

In vivo pharmaceutical analysis and pharmacokinetics of anti-HIV drugs

The successes and failures of HIV drug discovery